1 Steering committee member and leading investigator: A Phase I/Ib, Open-Label Study of Pevonedistat (MLN4924) as Single Agent and in Combination with Azacitidine in Adult Asian Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome (ClinicalTrials.gov Identifier: NCT02782468)
2 Country principal Investigator: Infusion of CD19-Specific Chimeric Antigen Receptor T Cells Produced by Rapid Personalized Manufacture for Patients with Advanced Lymphoid Malignancies. (Clinicaltrials.gov Identifier: NCT04844086)
3 Country principal Investigator: A Phase 1/2 multicenter, open-label, single-arm study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell (CD19 CAR-T) therapy in patients with relapsed or refractory B-cell lymphoma. (NTUH IRB Number: 202103027DSC)
4 Country Sub-Investigator: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA). (Clinicaltrials.gov Identifier: NCT03570892)
5 Country Sub-Investigator: A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients with Refractory or Relapsed Follicular Lymphoma. (Clinicaltrials.gov Identifier: NCT03568461)
6 Expert panelist: Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021 Nov;35(11):3059-3072.